A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer

NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer.
The primary hypotheses are:
The combination of NUC-1031 plus cisplatin prolongs overall survival compared to the gemcitabine plus cisplatin standard of care
The combination of NUC-1031 plus cisplatin increases overall response rate compared to the gemcitabine plus cisplatin standard of care

开始日期2019-12-24

申办/合作机构

NuCana Plc

NCT03146663 / Terminated临床2期

A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer

This study was designed to evaluate the effect of two dose levels of NUC-1031 (500 mg/m2 and 750mg/m2) in patients with ovarian cancer. The primary objective was to determine the anti-tumor activity of NUC-1031 at the selected dose level (500 mg/m2 or 750 mg/m2).

开始日期2017-09-28

申办/合作机构

NuCana Plc

NCT02351765 / Completed临床1期

A Phase Ib, Multi-centre, Open-label Study of a First-in-class Nucleotide Analogue Acelarin (NUC-1031) in Combination With Cisplatin in Patients With Locally Advanced/Metastatic Biliary Tract Cancers

The purpose of this study is to determine the recommended phase II dose, and to assess the safety of acelarin in combination with cisplatin in patients with locally advanced/ metastatic biliary tract cancers.

开始日期2016-01-01

申办/合作机构

The Christie Pathology Partnership LLP

100 项与 Fosgemcitabine palabenamide 相关的临床结果

登录后查看更多信息

100 项与 Fosgemcitabine palabenamide 相关的转化医学

登录后查看更多信息

100 项与 Fosgemcitabine palabenamide 相关的专利（医药）

登录后查看更多信息

项与 Fosgemcitabine palabenamide 相关的文献（医药）

2023-03-23·Journal of medicinal chemistry1区 · 医学

Design, Synthesis, and Anti-Cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine

1区 · 医学

Article

作者: Wang, Xuejian ; Xu, Jie ; He, Zengguo ; Li, Xiaoyang ; Jiang, Yuqi ; Xing, Yan ; Tong, Ling ; Qi, Kangjing ; Xu, Wenfang ; Zhang, Liang

ProTide and cyclic phosphate ester are two successful prodrug technologies to overcome the limitations of nucleoside drugs, among which the cyclic phosphate ester strategy has not been widely used in the optimization of gemcitabine. Herein, we designed a series of novel ProTide and cyclic phosphate ester prodrugs of gemcitabine. Cyclic phosphate ester derivative 18c exhibits much higher anti-proliferative activity than positive control NUC-1031 with IC₅₀s of 3.6-19.2 nM on multiple cancer cells. The metabolic pathway of 18c demonstrates that 18c's bioactive metabolites prolong its anti-tumor activity. More importantly, we separated the two P chiral diastereomers of gemcitabine cyclic phosphate ester prodrugs for the first time, revealing their similar cytotoxic potency and metabolic profile. 18c displays significant in vivo anti-tumor activity in both 22Rv1 and BxPC-3 xenograft tumor models. These results suggest that compound 18c is a promising anti-tumor candidate for treating human castration-resistant prostate and pancreatic cancer.

2022-06-01·Acta biomaterialia1区 · 工程技术

CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy

1区 · 工程技术

Article

作者: Sun, Yinping ; Zhong, Zhiyuan ; Wei, Jingjing ; Meng, Fenghua ; Guo, Beibei ; Wang, Jingyi ; Yuan, Jiandong

Gemcitabine (GEM) is among the most used chemotherapies for advanced malignancies including non-small cell lung cancer. The clinical efficacy of GEM is, however, downplayed by its poor bioavailability, short half-life, drug resistance, and dose-limiting toxicities (e.g. myelosuppression). In spite of many approaches exploited to improve the efficacy and safety of GEM, limited success was achieved. The short A6 peptide (sequence: Ac-KPSSPPEE-NH₂) is clinically validated for specific binding to CD44 on metastatic tumors. Here, we designed a robust and CD44-specific GEM nanotherapeutics by encapsulating hydrophobic phosphorylated gemcitabine prodrug (HPG) into the core of A6 peptide-functionalized disulfide-crosslinked micelles (A6-mHPG), which exhibited reduction-triggered HPG release and specific targetability to CD44 overexpressing tumor cells. Interestingly, A6 greatly enhanced the internalization and inhibitory activity of micellar HPG (mHPG) in CD44 positive A549 cells, and increased its accumulation in A549 cancerous lung, leading to potent repression of orthotopic tumor growth, depleted toxicity, and marked survival benefits compared to free HPG and mHPG (median survival time: 59 days versus 30 and 45 days, respectively). The targeted delivery of gemcitabine prodrug with disulfide-crosslinked biodegradable micelles appears to be a highly appealing strategy to boost gemcitabine therapy for advance tumors. STATEMENT OF SIGNIFICANCE: Gemcitabine (GEM) though widely used in clinics for treating advanced tumors is associated with poor bioavailability, short half-life and dose-limiting toxicities. Development of clinically translatable GEM formulations to improve its anti-tumor efficacy and safety is of great interest. Here, we report on CD44-targeting GEM nanotherapeutics obtained by encapsulating hydrophobic phosphorylated GEM prodrug (HPG), a single isomer of NUC-1031, into A6 peptide-functionalized disulfide-crosslinked micelles (A6-mHPG). A6-mHPG demonstrates stability against degradation, enhanced internalization and inhibition toward CD44⁺ cells, and increased accumulation in A549 lung tumor xenografts, leading to potent repression of orthotopic tumor growth, depleted toxicity and marked survival benefits. The targeted delivery of GEM prodrug using A6-mHPG is a highly appealing strategy to GEM cancer therapy.

2022-03-15·Environmental science & technology1区 · 环境科学与生态学

Insects as Chemical Sensors: Detection of Chemical Warfare Agent Simulants and Hydrolysis Products in the Blow Fly Using LC-MS/MS

1区 · 环境科学与生态学

Article

作者: Skaggs, Christine L. ; Manicke, Nicholas E. ; Moctar, Khadija ; Owings, Charity G. ; Picard, Christine J. ; Dowling, Sarah N.

In this work, blow flies were investigated as environmental chemical sample collectors following a chemical warfare attack (CWA). Blow flies sample the environment as they search for water and food sources and can be trapped from kilometers away using baited traps. Three species of blow flies were exposed to CWA simulants to determine the persistence and detectability of these compounds under varying environmental conditions. A liquid chromatography mass spectrometry (LC-MS/MS) method was developed to detect CWA simulants and hydrolysis products from fly guts. Flies were exposed to the CWA simulants dimethyl methylphosphonate and diethyl phosphoramidate as well as the pesticide dichlorvos, followed by treatment-dependent temperature and humidity conditions. Flies were sacrificed at intervals within a 14 day postexposure period. Fly guts were extracted and analyzed with the LC-MS/MS method. The amount of CWA simulant in fly guts decreased with time following exposure but were detectable 14 days following exposure, giving a long window of detectability. In addition to the analysis of CWA simulants, isopropyl methylphosphonic acid, the hydrolysis product of sarin, was also detected in blow flies 14 days post exposure. This work demonstrates the potential to obtain valuable samples from remote or access-restricted areas without risking lives.

项与 Fosgemcitabine palabenamide 相关的新闻（医药）

2024-08-30

·FierceBiotech

Another of NuCana's retooled chemotherapies is unable to increase survival in the clinic

"We believe it will be difficult to regain investor interest in the program in other ongoing studies," William Blair analysts concluded. NuCana has seen another of its reworked chemotherapies struggle to prove itself in the clinic, halving the biotech’s stock in post-market trading.The company had been testing NUC-3373—a new chemical entity derived from the widely used chemotherapy ingredient nucleoside analog 5-fluorouracil—in combination with leucovorin, irinotecan and bevacizumab to treat colorectal cancer in the phase 2 NuTide:323 study.But, in a post-market release Aug. 29, the Scottish company announced that the study’s steering committee had decided the combo regimen was unlikely to demonstrate superior progression-free survival compared to the control arm of fluorouracil, leucovorin, irinotecan and bevacizumab.NuCana had been hoping to develop NUC-3373 as a replacement for fluorouracil as a treatment for second-line colorectal cancer, according to the steering committee’s chair Josep Tabernero, M.D., Ph.D.“The premise of this ambitious goal was based on robust non-clinical and clinical data and the NuTide:323 study team are very disappointed with this outcome,” Tabernero said in the release.As a result, NuCana will discontinue the NuTide:323 study. CEO Hugh Griffith described the committee’s conclusion as an “unexpected outcome.”“These results highlight the challenges associated with developing new medicines for patients with complex and heterogenous cancers such as metastatic colorectal cancer,” Griffith said. “We will leverage insights from these data to identify future potential development options for NUC-3373 in colorectal cancer.” A favorable safety profile was observed in all three arms of the study, with only 12 of the 175 patients—four patients in each arm—discontinuing treatment due to adverse events, the biotech pointed out.NuCana has run into similar issues before. Acelarin, the company’s retooled version of Eli Lilly’s chemotherapy Gemzar, was deemed unlikely to successfully complete either a phase 3 metastatic pancreatic cancer trial in 2019 or a late-stage biliary cancer study in 2022. The candidate has since been removed from the biotech’s pipeline.Acelarin, NUC-3373 and NuCana’s other clinical-stage candidate NUC-7738 all use the same ProTide technology, although they are based on different molecules with distinct modes of action. Data from a phase 2 trial of NUC-7738 in combination with Keytruda in patients with melanoma is due to be unveiled next month.“The results of the NuTide:323 study do not impact the ongoing NuTide:303 study, in which NUC-3373 is being combined with either pembrolizumab in solid tumors or docetaxel in patients with lung cancer,” Griffiths added in the release. “Furthermore, we are excited about the potential of NUC-7738, a novel agent that profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment.” That excitement didn’t appear to be enough to reassure investors, who sent NuCana’s shares plunging 48% in the wake of the news, from $7.73 at market close on Thursday to $4 in post-market trading later that day.“Given this was the first controlled trial with NUC-3373, we believe it will be difficult to regain investor interest in the program in other ongoing studies,” William Blair analysts concluded in a note late yesterday evening.“The failures of the company’s phase 3 study with Acelarin and the randomized phase 2 study of NUC-3373 potentially increase perceived risk for the pipeline, and the data with NUC-3373 and NUC-7738 to date have come from single-arm studies, which have the potential to generate biased results,” the analysts added. “In addition, the long-term safety profile of NUC-3373 and other ProTides in the company’s pipeline needs to be established.”

临床2期临床3期临床结果临床终止临床失败

2021-09-16

·BioSpace

Global Roundup: TreeFrog Scores $75 Million, Establishes US Toehold

France’s TreeFrog Therapeutics, a privately-held biotech startup, closed a $75 million (€64M) Series B financing round, named a new chief executive officer and established an office in Boston to gain a U.S. toehold. TreeFrog is developing stem cell-derived cell therapies developed with the company’s C-Stem platform. Data published in multiple journals indicated C-Stem is the only technology capable of maintaining genomic integrity through large-scale human-induced pluripotent stem cells (hiPSC) expansion. Based on best-in-class preclinical results in Parkinson's disease, TreeFrog Therapeutics is preparing for a first-in-human trial in 2024, and intends to expand its pipeline of cell therapies through in-house programs and partnerships. With the infusion of funds, TreeFrog brought in Frederic Desdouits as its new CEO. Desdouits had been serving as an independent director of the board. He previously served as CEO of PCAS and managing director at Seqens CDMO. Before that, Desdouits was executive vice president, Corporate Licensing, Acquisition and Market Intelligence, and director of U.S. Pharmaceuticals, Pierre Fabre Group. The Series B round was led by Bpifrance Large Venture, which is part of the French Public Investment Bank. Leonard Green & Partners, Bristol Myers Squibb and Xange also joined in the round. It was also announced that Kevin Alessandri, co-founder of the company, will relocate in early 2022 to Boston to lead the newly created U.S. subsidiary, TreeFrog Therapeutics Inc. Relief Therapeutics – Switzerland-based RELIEF Therapeutics received updated guidance regarding potential conditional marketing authorization from the U.K.’s Medicines and Healthcare products Regulatory Agency regarding the development of its lead investigational drug, RLF-100 (aviptadil), for the treatment of respiratory deficiency due to severe COVID-19. Based on the meeting, the company believes such an authorization through a rolling review or expedited process will be appropriate. A rolling review allows the MHRA to start review of various sections of a submission as they are completed by Relief and provided to the MHRA. HutchMed – China’s HutchMed announced the Center for Drug Evaluation, a part of China’s National Medical Products Administration, granted Breakthrough Therapy Designation to amdizalisib (HMPL-689), a highly selective and potent PI3Kδ inhibitor, for the treatment of relapsed or refractory follicular lymphoma (FL), a subtype of non-Hodgkin’s lymphoma (NHL). To date, amdizalisib has been shown to be well tolerated, exhibiting dose-proportional pharmacokinetics, a manageable toxicity profile, and single-agent clinical activity in relapsed/refractory B-cell lymphoma patients. Amdizalisib is also being evaluated in an ongoing Phase I/Ib study in the U.S. and Europe in patients with relapsed or refractory NHL. CytoLynx Therapeutics – The new China-based subsidiary of Cytovia Therapeutics closed a $45 million investment round that will finance the IND-enabling and clinical development of the company’s pipeline. The company is developing allogeneic “off-the-shelf” gene-edited iNK and CAR (Chimeric Antigen Receptor)-iNK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies. The financing was supported by TF Capital along with YF Capital, BioTrack Capital, Ruihua Capital, and TG Sino-Dragon Fund. AGC Biologics – Germany-based AGC Biologics is expanding its Heidelberg facility in order to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects. With this expansion, AGC Biologics is boosting its current 100L and 1,000L manufacturing capacities for a variety of different biologics projects by adding an additional GMP manufacturing line. The expansion includes a new GMP cleanroom for mRNA development and manufacturing, a new process development lab for microbial protein and cell and gene therapy (C>) projects, and additional warehouse capacity. The expanded capabilities will also allow AGC Biologics to meet the increasing demands of the rapidly growing C> market. The facility's new capabilities will be fully operational in 2023. Telix Pharmaceuticals – Australia-based Telix announced the U.S. Food and Drug Administration accepted an Investigational New Drug Application for its investigational kidney cancer therapy, TLX250 (177Lu-DOTA-girentuximab). The drug will be assessed in the Phase II STARLITE 2 study in patients with advanced clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer. TLX250 targets carbonic anhydrase IX (CA9), a protein that is highly expressed in patients that are likely to demonstrate a more limited response to cancer immunotherapy. Zai Lab Limited – China’s Zai Lab announced that the Center for Drug Evaluation of the National Medical Products Administration granted Breakthrough Therapy Designation for bemarituzumab, for first-line treatment for patients with FGFR2b overexpressing and human epidermal growth factor receptor (HER2)-negative metastatic and locally advanced gastric and GEJ cancers in combination with modified FOLFOX6 (fluoropyrimidine, leucovorin, and oxaliplatin). Abivax– France-based Abivax SA provided additional analysis of data regarding its lead compound ABX464 in ulcerative colitis. According to the latest additional analysis, the results after 16 weeks of once-daily oral treatment with ABX464 confirm and further extend the data with respect to the efficacy and the good safety pro observed after 8-weeks of induction treatment. That data was initially announced in May. The baseline disease characteristics were well balanced across all ABX464 dose groups and the placebo group. Enrolled patients suffered from longstanding UC with an overall median duration of 5.45 years. At inclusion, 71.4% of the patients showed a severe disease profile, with a baseline modified Mayo Score of 7 to 9 points. About 50% of the patients in each ABX464 treatment group and placebo were previously refractory to biologic treatments and/or JAK inhibitors. The majority of the patients was treated with concomitant UC medication at a stable dose. ObsEva SA – Switzerland’s ObsEva announced it submitted a New Drug Application to the FDA for linzagolix for the treatment of uterine fibroids. Linzagolix is an oral GnRH receptor antagonist with potential best-in-class efficacy, favorable tolerability profile, and unique and flexible dosing options. If approved, linzagolix will be the only GnRH antagonist in uterine fibroids with a low dose non-add-back therapy (ABT) option. Data is based on the Phase III PRIMROSE 1 and PRIMROSE 2 studies. In both clinical studies, all doses showed statistically significant and clinically relevant reductions in HMB compared to placebo. Biophytis SA – France-based Biophytis AS announced the Data Monitoring Committee cleared its Phase II/III COVA study in COVID-19 to continue. The COVA study primary endpoint is the proportion of participants with “negative events” of either the following: all cause mortality; respiratory failure defined as requiring mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO). Sensorion – Also based in France, Sensorion forged a collaboration with Sonova to introduce genetic analysis to the routine diagnosis of progressive hearing loss in adults. The key element of the collaboration is a natural history study including genotyping thousands of patients suffering from early onset of severe age-related hearing loss with the aim of confirming hundreds of patients for specific mutations. NuCana – Scotland-based NuCana plc completed enrollment in its Phase III NuTide:121 study. The study, is comparing Acelarin combined with cisplatin to the global standard of care, gemcitabine plus cisplatin, as a first-line treatment for patients with advanced biliary tract cancer, has enrolled 418 patients with measurable disease. The first interim analysis will be conducted after the 418th patient has completed 28 weeks of follow-up, which is expected to occur in the first half of 2022. Gedea Biotech – Sweden’s Gedea has enrolled more than 50% of patients in the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). Bacterial vaginosis is the most common vaginal infection and affects around 10-30% of women of reproductive age.

基因疗法抗体突破性疗法细胞疗法免疫疗法

2020-03-10

·BioPortfolio

NuCana plc: NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer

Confirmed Complete Response and Two Partial Responses Achieved in Heavily Pre-treated Population Patients had Median of Five Prior Lines of Therapy EDINBURGH, United Kingdom, March 10, 2020 (GLOBE ...

100 项与 Fosgemcitabine palabenamide 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15057

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期胆管癌	临床3期	美国	NuCana Plc	2019-12-24
晚期胆管癌	临床3期	澳大利亚	NuCana Plc	2019-12-24
晚期胆管癌	临床3期	加拿大	NuCana Plc	2019-12-24
晚期胆管癌	临床3期	捷克	NuCana Plc	2019-12-24
晚期胆管癌	临床3期	法国	NuCana Plc	2019-12-24
晚期胆管癌	临床3期	德国	NuCana Plc	2019-12-24
晚期胆管癌	临床3期	匈牙利	NuCana Plc	2019-12-24
晚期胆管癌	临床3期	意大利	NuCana Plc	2019-12-24
晚期胆管癌	临床3期	俄罗斯	NuCana Plc	2019-12-24
晚期胆管癌	临床3期	韩国	NuCana Plc	2019-12-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04163900 (NuTide:121, ESMO_GI2023)	临床3期	晚期胆管癌一线	773	NUC-1031+cisplatin	顧鑰夢鹹觸鏇願淵觸壓(顧壓遞齋製膚觸鬱餘衊) = 獵構憲憲膚糧鏇襯構鹽廠鬱簾鏇構糧繭餘鏇鹽 (襯膚獵衊積繭糧積鑰繭 ) 更多	不佳	2023-07-01
				Gemcitabine+cisplatin	顧鑰夢鹹觸鏇願淵觸壓(顧壓遞齋製膚觸鬱餘衊) = 築構築廠觸鑰鬱膚遞糧廠鬱簾鏇構糧繭餘鏇鹽 (襯膚獵衊積繭糧積鑰繭 ) 更多
NCT04163900 (NuTide:121, CTgov)	临床3期	晚期胆管癌 \| 转移性胆道癌	773	cisplatin+NUC-1031 (A - NUC-1031 and Cisplatin)	膚夢鑰願網獵鹽範窪淵(鏇醖膚夢夢築鏇構蓋襯) = 築積鑰鹽觸網淵顧鏇憲積廠積淵憲獵夢選壓衊 (築觸淵鑰製齋淵鬱製襯, 蓋憲鬱網衊顧鹽鹽憲蓋 ~ 夢糧蓋築簾鏇顧獵醖鹹) 更多	-	2023-05-24
				Gemcitabine+cisplatin (B - Gemcitabine and Cisplatin)	膚夢鑰願網獵鹽範窪淵(鏇醖膚夢夢築鏇構蓋襯) = 觸繭鹹鹹壓襯繭夢襯襯積廠積淵憲獵夢選壓衊 (築觸淵鑰製齋淵鬱製襯, 構醖獵願顧淵繭衊鏇鹹 ~ 蓋糧齋餘積憲糧襯構糧) 更多
NCT04163900 (NuTide:121, ESMO2021)	临床3期	晚期胆管癌一线	828	NUC-1031 + cisplatin	製築顧襯廠鏇獵繭齋鑰(積製蓋觸窪選製蓋簾齋) = 襯鏇齋蓋鬱築蓋鹹齋積築製襯醖憲選簾製積艱 (構鑰鏇齋窪廠鑰廠築醖 )	-	2021-09-16
				Gemcitabine + cisplatin	製築顧襯廠鏇獵繭齋鑰(積製蓋觸窪選製蓋簾齋) = 鹽廠製衊觸網遞鑰鑰築築製襯醖憲選簾製積艱 (構鑰鏇齋窪廠鑰廠築醖 )
NCT02303912 (Pubmed \| Clin Cancer Res) 人工标引	临床1期	复发性卵巢癌	25	Carboplatin+NUC-1031	繭齋糧齋繭顧鹹範蓋蓋(蓋鹹蓋鬱遞觸鹹鏇鹽膚) = NUC-1031（500 mg/m2 ）艱窪憲顧餘鹽鬱艱獵網 (鏇願鹽鑰壓範廠鹹築願 )	积极	2021-06-01
NCT02351765 (ABC-08, Pubmed) 人工标引	临床1期	晚期胆管癌一线	20	Cisplatin+NUC-1031	觸齋齋醖築顧築鹹蓋衊(構鑰鑰齋鹹衊簾淵築餘) = NUC-1031 725 mg/m2 遞鏇鏇壓膚簾鹹膚蓋襯 (鹽淵繭築艱製壓網壓鬱 ) 更多	积极	2021-04-01
NCT03146663 (CTgov)	临床2期	铂耐药性卵巢癌	53	NUC-1031 500 mg (Arm A)	齋鑰夢膚選選願蓋餘餘(鑰網夢鏇鑰淵網築鹹鏇) = 膚糧鏇積簾壓艱鏇網醖鹽鹹鑰簾簾遞蓋餘艱襯 (淵廠範壓鬱鏇鏇艱觸製, 淵艱築範廠鏇積鹹襯遞 ~ 壓夢壓齋繭鬱壓積鑰糧) 更多	-	2021-02-21
				NUC-1031 750mg (Arm B)	齋鑰夢膚選選願蓋餘餘(鑰網夢鏇鑰淵網築鹹鏇) = 簾餘餘願遞齋鹽願鹽範鹽鹹鑰簾簾遞蓋餘艱襯 (淵廠範壓鬱鏇鏇艱觸製, 衊積壓製壓糧夢淵窪構 ~ 鏇膚壓憲願廠構製齋糧) 更多
PRO-002 and ABC-08 (ASCO2019)	N/A	卵巢癌 \| 晚期胆道癌一线	-	NUC-1031 + carboplatin	範顧艱遞鹹構鏇壓鑰鹽(築蓋醖構糧簾製選選範) = DLTs were myelosuppression and fatigue 廠範範簾膚糧選遞艱窪 (願憲遞夢鹹選製憲構遞 ) 更多	积极	2019-05-26
				NUC-1031 + cisplatin
NCT02351765 (ASCO2019)	临床3期	晚期胆管癌一线	828	NUC-1031 + cisplatin	觸淵繭製繭齋餘願憲網(蓋衊製選憲襯網艱鹽餘) = 觸襯網網繭簾選鏇廠簾網範獵鏇廠蓋網願鏇構 (餘壓窪製憲壓觸壓糧簾 )	-	2019-05-26
NCT01621854 (Pubmed \| Med J Aust) 人工标引	临床1期	晚期癌症	49	Nuc-1031	鏇簾鑰鑰齋淵醖醖繭憲(餘壓鹹製製淵鹽鹽壓範) = 鹹壓壓繭窪鬱齋窪齋膚鏇觸選醖遞觸鑰顧願顧 (製積鏇淵壓製築範膚憲 ) 更多	积极	2018-10-01
NCT02303912 (ASCO2016)	临床1期	复发性卵巢癌	15	Acelarin + Carboplatin (AUC 4 or 5)	獵壓壓夢構選構襯構築(壓範遞淵艱窪蓋觸憲齋) = 窪廠窪構齋積網願襯窪窪膚繭觸獵積襯艱壓選 (遞憲網艱淵衊膚範範鏇, 1.2 ~ 11.5) 更多	积极	2016-05-20